
Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors
Shots: The first patient has been dosed in a P-I CIBI323A101 study evaluating IBI323 (anti-LAG-3/PD-L1 bispecific Ab) in patients with advanced solid tumors. The trial […]